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Abstract To clarify the effect of hepatocyte growth factor
(HGF) on proliferation of hepatic oval cells, we transferred HGF
gene into liver of the Solt^Farber rat model. Male Fisher 344
rats were infected with a recombinant adenovirus carrying the
cDNA for HGF (pAxCAHGF) from tail vein. HGF mRNA
showed its peak at 4 days, and diminished thereafter. The total
and proliferating cell nuclear antigen-positive hepatic oval cells
were significantly elevated in HGF-transferred rats, in which
stem cell factor and c-kit mRNA increased at each time point.
Our results suggest that in vivo transfer of the HGF gene into
liver accelerates proliferation of hepatic oval cells in the Solt^
Farber model in rats.
z 2000 Federation of European Biochemical Societies.
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1. Introduction
Liver regeneration is usually accomplished by the prolifer-
ation of di¡erentiated hepatocytes. However, when hepatocyte
proliferation is impaired, hepatic oval cells proliferate, invade
into the adjacent liver parenchyma, and di¡erentiate into hep-
atocytes or biliary epithelial cells [1^4]. One of the most
widely used models of oval cell activation is the modi¢ed
Solt^Farber regime [5,6]. In the presence of 2-acetylamino-
£uorene (2-AAF), oval cells rather than hepatocytes prolifer-
ate after 2/3 partial hepatectomy (PH), and oval cells play an
important role in liver regeneration when liver is severely
damaged and hepatocyte proliferation is inhibited. In humans,
oval cells which are similar in morphology and antigenic pro-
¢le to those seen in rodents emerge in many liver diseases
[2,7].
Oval cells express receptors for transforming growth factor
K (TGFK), TGFL, acidic ¢broblast growth factor and hepa-
tocyte growth factor (HGF) [2]. Although there seems to be a
paracrine loop between Ito cells and oval cells, oval cells may
be autonomous in their requirement for mitogens and morph-
ogens since putative embryological oval cell equivalents are
able to proliferate in serum-free conditions [8,9]. HGF, a po-
tent mitogen for mature hepatocytes, proved to be a multi-
functional growth factor [10^12]. HGF is a powerful mitogen
for mature hepatocytes and biliary epithelial cells [13,14].
Since HGF is a morphogen during embryological tissue devel-
opment [15], and therefore probably has a fundamental in£u-
ence on oval cell behavior. Indeed, HGF plays an important
role in the control of proliferation and di¡erentiation of eryth-
roid progenitor cells in fetal liver [16], and acts in synergy with
stem cell factor (SCF) [17]. There is evidence that hepatic oval
cells may be derived from bone marrow [18]. Since several
growth factors enhance the mitogenic response of oval cells
[19] and the SCF/c-kit system is an important regulator of
oval cell activation [20,21], we examined the e¡ect of HGF
gene transfer on hepatic oval cell proliferation, and also clari-
¢ed expression of SCF/c-kit in this situation.
2. Materials and methods
2.1. Chemicals and animals
2-AAF pellets (75 mg/pellet over a 21 day release) were purchased
from Innovative Research (Sarasota, FL, USA). Fisher 344 rats,
8 weeks old and adult males weighing 150^180 g, were obtained
from Charles River Japan (Yokohama, Japan). Rats were maintained
in a temperature-controlled room with a 12 h light/dark illumination
cycle. Rats were fed a CE-2 diet (CLEA Japan, Tokyo, Japan) and
were allowed to drink water ad libitum.
2.2. Construction of pAxCAHGF and pAxCALacZ
The cassette cosmid for constructing recombinant adenovirus of the
E1 substitution type is an 11 kb charomid vector bearing an Ad5
genome spanning (mu) 0^99.3 map units with deletions of E1
(mu1.3^9.3) and E3 (mu79.6^84.8) [22]. Two plasmids expressing rat
HGF [23] and Escherichia coli LacZ were constructed by inserting the
rat HGF gene and the LacZ gene downstream from the CAG pro-
motor, respectively. The CAG expression unit was inserted at the
deleted E1 region. After insertion of an expression unit into the cas-
sette cosmid, the cassette cosmid bearing an expression unit was co-
transfected into 293 cells, human embryonic kidney cells transformed
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by E1A and E1B genes, together with EcoT221-digested DNA-TPC of
Ad5-dlX. The construction of resulting recombinant adenoviruses
pAxCAHGF and pAxCALacZ was shown in Fig. 1. The reason
why we used adenovirus vector is that adenovirus infectivity to liver
is extremely high and adenovirus vectors are commonly used for in
vivo gene therapy in experimental liver disorders [24].
2.3. Experimental procedures
The experimental protocol is shown in Fig. 2. For induction of oval
cells, the rats were treated according to the method for the AAF/PH
model [5,6]. AAF is used as a mito-inhibitor for adult rat hepatocyte
in this model. Brie£y, 2-AAF pellets were subcutaneously inserted
7 days before 70% PH. Just after PH, pAxCAHGF (1U109 plaque
forming units (pfu)) or pAxCALacZ (1U109 pfu) in 0.1 ml of phos-
phate-bu¡ered saline (PBS) was administered into tail vein of rats
(group I). In rats of group II, 0.1 ml of PBS without pAxCAHGF
was administered into vein. Five rats each were killed at 4, 7, 9 and
13 days after PH. PH alone, AAF administration without PH, and
pAxCALacZ administration with AAF/PH regime were carried out as
controls. All surgical procedures were performed under sodium pen-
tobarbital anesthesia. Experimental procedures were approved by the
Animal Care Committee of Tottori University School of Medicine
and done in compliance with the guidelines of our university. Animals
received human care according to the criteria outlined in the ‘Guide
for the Care and Use of Laboratory Animals’ prepared by the Na-
tional Academy of Sciences and published by the National Institutes
of Health (NIH publication 86-23 revised 1985). The number of oval
cells was counted in 10 periportal areas selected randomly in each
specimen stained with hematoxylin and eosin by using NIH Image
1.55 (National Institutes of Health, USA). The value was expressed as
the number per periportal ¢eld (0.25U0.25 mm2). The proliferating
cell nuclear antigen (PCNA)-positive oval cells were counted in the
same way.
2.4. Reverse transcription-polymerase chain reaction (RT-PCR)
analysis
Total cellular RNA was isolated from snap-frozen liver tissue by
using ISOGEN (Nippon Gene Co., Toyama, Japan) according to the
manufacturer’s instructions. The RNA samples were digested with
DNase (Nippon Gene Co.) to remove DNA from the samples. 1 Wg
of RNA was converted to complementary DNA and was ampli¢ed by
using RNA LA PCR1 kit (TaKaRa, Kyoto, Japan) and a thermo-
cycler (Program Temp Control System PC-700, ASTEC, Japan).
Primer sequences for rat HGF, c-met, SCF, c-kit and glyceralde-
hyde-3-phosphate dehydrogenase (GAPDH), used in PCR on comple-
mentary DNA, size of PCR products and annealing temperature in
each reaction were shown in Table 1. The cycle number of PCR was
30 for all genes. The amount of expression of HGF mRNA was
determined by using the NIH image version 1.58 computer software
(Macintosh, USA).
2.5. Immunohistochemistry
Livers were ¢xed in 4% paraformaldehyde and embedded in paraf-
¢n. Sections (4 Wm thick) were incubated in 0.3% H2O2 in methanol
for 30 min. After washing in PBS, they were incubated with normal
horse serum or normal goat serum (Vector Laboratories, CA, USA).
The sections were then incubated with the following antibodies; a
mouse monoclonal antibody against human CK-19 (Novocastra
Laboratories, Newcastle, UK) diluted 1:40; a mouse monoclonal
antibody against rat OV-6 [25] diluted 1:10; a mouse monoclonal
antibody against human AFP (NEOMARKERS, Lab Vision Corpo-
ration, CA, USA) diluted 1:50; a mouse monoclonal antibody against
human c-kit protein (NEOMARKERS, Lab Vision Corporation, Fre-
mont, CA, USA) diluted 1:50; a mouse monoclonal antibody against
rat PCNA (NCL-PCNA, Novacastra Laboratories, Newcastle, UK)
diluted 1:100; a mouse monoclonal antibody against human desmin
(YLEM, Rome, Italy) diluted 1:50; goat polyclonal antibody against
SCF (Santa Cruz Biotechnology, CA, USA) diluted 1:100 and rabbit
IgG fraction against rat albumin (Inter-Cell Technologies, NJ, USA)
diluted 1:100, at 4‡C overnight. To facilitate antigen retrieval, sections
for the CK-19 and desmin immunostain were digested with 0.05%
trypsin (Sigma Chemical, MO, USA) in 0.1 mol/l Tris^HCl and
0.1% CaCl2, pH 7.8, for 5 min at 37‡C before staining. All the sec-
tions stained in the present study were heated in 10 mmol/l sodium
citrate bu¡er (pH 6.0) at 600 W for 15 min with a microwave oven.
After washing in PBS, sections were incubated with biotin-conjugated
horse anti-mouse or goat anti-rabbit immunoglobulin G (Vector Lab-
oratories) for 60 min. Immunoreacted cells were visualized by a Vec-
tastain ABC kit (Vector Laboratories). The expression of L-galacto-
sidase was assessed by X-gal staining [26].
2.6. Statistical analysis
Statistical signi¢cances were assessed using Mann^Whitney’s U test.
P6 0.05 was considered statistically signi¢cant.
3. Results
3.1. Expression of HGF mRNA and c-met mRNA
Serial analysis of HGF and c-met mRNA was performed
(Fig. 3). In group I, expression of HGF mRNA showed its
peak at 4 days after PH, and gradually decreased at 7 days
and 9 days. In group II, expression of HGF mRNA was
scarcely observed. Expression of HGF mRNA was much
greater in group I than that in group II. The amount of
HGF mRNA at 4 days was about 5-fold higher than that in
control liver 2 days after PH without AAF. c-met expressed at
a similar level between group I and II at 4 days, and slightly
higher in group I than in group II at 7 and 9 days.
Fig. 1. Construct of pAxCAHGF. Rat HGF cDNA was inserted in
CAG promotor driving adenovirus vector lacking E1A, E1B and
E3. In case of pAxVALacZ, LacZ cDNA was inserted instead of
HGF cDNA.
Fig. 2. Experimental schedule. 2-AAF: 2-acetylamino£uorene, PH:
70% partial hepatectomy.
Fig. 3. RT-PCR analysis of HGF and c-met mRNA expression.
GAPDH: glyceraldehyde-3-phosphate dehydrogenase, C: rat liver
with no treatment, PH: rat liver 2 days after PH without AAF ad-
ministration.
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3.2. Oval cell development
At 4 days after PH, small basophilic cells with a high nu-
clear:cytoplasmic ratio were evident around the portal tracts.
These cells increased in number with time. They fanned out
from each portal tract and penetrated deep into the liver aci-
nus surrounding preexisting acidophilic hepatocytes at 9 days
after PH. In AAF/PH rats in which pAxCALacZ was admin-
istered, expression of L-galactosidase was observed mostly in
hepatocytes, but not in oval cells (Fig. 4). These cells were
stained with anti-CK-19 antibody and anti-OV-6 antibody
(Fig. 5C,D), and also stained with anti-AFP antibody (data
not shown). At 9 days after PH, many and large clusters of
oval cells were seen in group I (Fig. 5A), on the other hand,
smaller and fewer clusters were seen in group II (Fig. 5B).
Treatment with PH alone or administration of AAF without
PH did not induce oval cells in rats (data not shown). In
addition, in AAF/PH rats in which pAxCALacZ was admin-
istered instead of pAxCAHGF, the total and PCNA-express-
ing oval cells were almost equal to those in group II (data not
shown). To evaluate the e¡ect of HGF expression on oval
cells, oval cells in the portal area were counted. The numbers
of oval cells at 4, 7, 9 and 13 days after PH were 18.0 þ 6.3,
147.0 þ 17.0, 200 þ 25.4 and 150.0 þ 38.0 in group II, res-
pectively. In group I, they were 19.7 þ 2.9, 192.0 þ 23.0,
410.0 þ 44.7 and 374.0 þ 93.1, respectively. Although oval cells
reached their peak in number at 9 days, they were signi¢cantly
increased in group I at 7, 9 and 13 days, compared to in group
II (P6 0.05, P6 0.01 and P6 0.01, respectively, Fig. 6A).
Furthermore, to assess the proliferating activity of oval cells
in these livers, liver sections were stained with anti-PCNA
antibody. PCNA-stained cells were restricted to the oval cells
in the liver acinus (Fig. 7D). Interestingly, positive rates for
Table 1
Primers and annealing temperature of PCR




HGF sense: 5P-ATGCTCATGGACCCTGGT-3P antisense: 5P-GCCTGGCAAGCTTCATTA-3P 423 55
c-met sense: 5P-CAGTGATGATCTCAATGGGCAAT-3P antisense: 5P-AATGCCCTCTTCCTATGACTTC-3P 725 58
SCF sense: 5P-CCGGGATGGATGTTTTGC-3P antisense: 5P-TGCAACAGGGGGTAACAT-3P 382 55
c-kit sense: 5P-TGCTCTGCGTCCTGTTGGTC-3P antisense: 5P-CCTGGCGTTCGTAATTGAAGTC-3P 794 55
GAPDH sense: 5P-CCTTCATTGACCTCAACTAC-3P antisense: 5P-GGAAGGCCATGCCAGTGAGC-3P 496 57
Fig. 4. Immunohistochemical staining of expression of L-galactosidase. The liver of rats at 7 days after pAxCAlacZ injection was used (U200).
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PCNA in oval cells of both groups were high, reaching about
90% at 4 days, and reducing with time. The numbers of
PCNA-positive oval cells at 4, 7, 9 and 13 days in group II
were 16.4 þ 5.7, 78.0 þ 10.2, 65.0 þ 8.3 and 21.5 þ 5.4, respec-
tively. On the other hand, in group I, they were increased to
17.2 þ 2.5, 126.7 þ 15.2, 142.0 þ 15.6 and 64.0 þ 15.9, respec-
tively (Fig. 6B). Taken together, activation and expansion of
oval cell population is enhanced by increased expression of
HGF.
3.3. SCF and c-kit expression
Since SCF/c-kit has been reported to play an important role
in development of oval cells in the AAF/PH model, expression
of SCF and c-kit was examined in rat livers from group I and
II (Fig. 8). As shown in Fig. 8, SCF mRNA was strongly
expressed at 4 and 7 days after PH in group I, however, a
small amount of SCF mRNA was also observed in group II.
Fig. 5. Immunohistochemical analysis of oval cells. A: Hematoxylin and eosin staining of liver tissue from 9 days after PH in group I (U40).
The arrows show the cluster of oval cells. B: Hematoxylin and eosin staining of liver tissue from 9 days after PH in group II (U40). The ar-
row shows the cluster of oval cells. C: CK-19 staining at 9 days after PH in group I (U100). The arrow shows the CK-19-expressing oval cells.
Oval cells were stained with anti-CK-19 antibody. D: OV-6 staining at 9 days after PH in group I (U200). Oval cells were stained with anti-
OV-6 antibody.
6
Fig. 6. Serial changes of oval cells and PCNA-expressing oval cells.
(A) Oval cell number in group I and II. The number of oval cells
was counted in 10 periportal areas selected randomly in each speci-
men stained with hematoxylin and eosin by using NIH Image 1.55
(National Institutes of Health, USA). The value was expressed as
the number per periportal ¢eld (0.25U0.25 mm2). (B) PCNA-posi-
tive oval cell number in group I and II. The PCNA-positive oval
cells were counted in the same way.
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Expression of c-kit mRNA in group I was higher than that in
group II at each time point. Western blot analysis also showed
that c-kit protein was strongly expressed in livers from group
I, especially at 9 days after PH (data not shown). Ito cells,
which stain positively for desmin, have been shown to be
closely associated with the development of oval cells in the
AAF/PH model [21]. We examined their association with oval
cells by staining Ito cells with desmin. The desmin-positive Ito
cells were observed in the proximity of oval cells (data not
shown). c-kit protein-expressing cells were oval cells and bili-
ary epithelial cells in the portal area (Fig. 7A,B). In addition,
SCF protein was also expressed in oval cells and biliary epi-
thelial cells (Fig. 7C). These data suggest that SCF and c-kit
on oval cells act in an autocrine fashion.
4. Discussion
Oval cells are undoubtedly important for liver regeneration
in severely injured liver. Oval cells emerge in situations where
mature hepatocytes cannot proliferate, and they di¡erentiate
into hepatocytes [1^4]. In addition, in submassive necrosis, a
typical feature of fulminant hepatic failure, and in human
diseased liver, oval cells emerge in the portal area, suggesting
that oval cells play a critical role in human liver regeneration
[27]. Oval cells isolated from LEC rats di¡erentiate into albu-
min-producing hepatocytes when returned to the livers of
LEC/NAGASE analbuminemic double mutant rats [28].
This observation is very intriguing, since the authors pre-
sented the possibility that oval cells can be used as powerful
tool to cure patients with hypoalbuminemia.
In the present study, we demonstrated that HGF gene
transfer into liver causes increased proliferation of oval cells.
Although HGF was initially found to be a mitogen for hep-
atocytes in vitro, it also proved to be a potent mitogen in
vivo. We developed transgenic mice expressing HGF in liver
Fig. 7. Immunohistochemical study of oval cells. A: c-kit was expressed in oval cells and biliary epithelial cells (U40). The arrow shows the
c-kit-expressing oval cells. B: c-kit was expressed in oval cells and bile duct epithelial cells (U400). The biliary epithelial cells are also positive
for c-kit (arrow). C: SCF was expressed in oval cells and biliary epithelial cells (U200). The arrow shows the SCF-positive oval cells.
D: PCNA was expressed in oval cells in portal area (U100).
Fig. 8. Expression of SCF mRNA and c-kit mRNA. Analysis of
SCF mRNA and c-kit mRNA was done by RT-PCR. C: rat liver
with no treatment, PH: rat liver 2 days after PH without AAF ad-
ministration.
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[29]. Using these mice, we demonstrated that HGF accelerates
liver regeneration, protects against D-galactosamine-induced
liver injury, and inhibits growth of c-myc-induced hepatocel-
lular carcinoma, suggesting that HGF is active in vivo as well
as in vitro [29^31]. In addition, gene therapy by HGF was
reported to be potentially useful for treatment of experimental
liver cirrhosis in rats [32]. In the present study, albumin-pro-
ducing cells eventually appeared in oval cell population
around portal ¢eld at 13 days in group I (data not shown).
It is possible that HGF stimulates di¡erentiation of the oval
cells into hepatocytes. Taken together, ex vivo or in vivo gene
therapy by HGF may be promising for treatment of liver
diseases refractory to conventional therapy.
Why SCF and c-kit were up-regulated in the rat livers in
group I remains to be resolved. There are two possibilities.
Firstly, HGF directly stimulates SCF/c-kit via HGF/c-met
signaling, resulting in activation of oval cells. Secondly,
HGF activates oval cell proliferation, resulting in a concom-
itant and autocrine increase of SCF/c-kit. Recently, Matsusa-
ka et al. have reported that the SCF/c-kit system plays an
important role in development of oval cells, but re£ecting a
small role in stimulating proliferation of oval cells [21]. In the
present study, in vivo transfer of HGF gene results in over-
expression of SCF and c-kit in oval cells, suggesting oval cell
activation and proliferation by HGF may be closely linked to
the SCF/c-kit system.
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